C.M. Bidwell & Associates’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

C.M. Bidwell & Associates’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-3,815	Closed	-$80K	–	463
2018 Q1	$80K	Sell	3,815 -9,865	-72%	-$192K	0.07%	212
2017 Q4	$198K	Sell	13,680 -4,330	-24%	-$66.9K	0.17%	167
2017 Q3	$284K	Buy	+18,010	New	+$264K	0.44%	89
2017 Q1	–	Sell	-16,175	Closed	-$244K	–	295
2016 Q4	$244K	Buy	+16,175	New	+$228K	0.06%	139

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

C.M. Bidwell & Associates's ITCI Position: Q2 2018 in Review

C.M. Bidwell & Associates sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2018, closing a stake of 3,815 shares — an estimated $80K sold.

C.M. Bidwell & Associates first reported a position in ITCI in Q4 2016 and held it in 4 quarters. The position peaked at $284K in Q3 2017. 131 funds tracked by Wall St. Rank hold ITCI as of Q2 2018.

C.M. Bidwell & Associates reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2018 after selling out during the quarter.
C.M. Bidwell & Associates sold 3,815 Intra-Cellular Therapies Inc. shares in Q2 2018, an estimated $80K.
C.M. Bidwell & Associates first reported a position in Intra-Cellular Therapies Inc. in Q4 2016 and held it in 4 quarters.
C.M. Bidwell & Associates's Intra-Cellular Therapies Inc. position peaked at $284K in Q3 2017.
131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2018.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2018, filed 13 Aug 2018.